Seoul Semiconductor Wins 'No Wire' LED Patent Lawsuit Across Europe
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a leading global innovator of LED products and technology, and its affiliate Seoul Viosys (together “Seoul”), announces that it has won a patent litigation case against Everlight, a Taiwanese LED company ranked 6th globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925330051/en/
Seoul Semiconductor's WICOP_ No wire, a robust and highly-efficient structure (Graphic: Seoul Semiconductor Co., Ltd.)
In August 2024, the Boards of Appeal of the European Patent Office (EPO) dismissed Everlight’s patent invalidation action against Seoul’s WICOP patent - No Wire LED technology. This decision has once again confirmed the strength of the WICOP patent portfolios registered across 18 European countries.
Since the ruling of the UK Patents Court in 2018, Seoul has won all patent lawsuits against Everlight and its distributor. These victories have spanned across five countries over the past seven years. Seoul has won lawsuits related to WICOP technology applied in lighting, automotive, and display applications, as well as those involving fundamental LED patents, thereby gaining recognition for the strength of Seoul’s patented technology.
The No Wire LED technology is an essential technology used not only in display products such as Micro LEDs, but also in new technologies like ADB headlamps and STOP lamps that communicate with and help protect drivers and pedestrians in the automotive sector.
LEDs opened a new era for optical semiconductors with the development of blue and white LEDs by Dr. Shuji Nakamura, a Nobel Prize-winning physicist, contributing to longer lifespans and energy savings across various applications. However, many companies have focused solely on price competitiveness and performance in LED development, ignoring some of the potential health impacts of certain lighting.
Seoul has invested nearly $100 million annually, which is 10% of its sales, in research and development (R&D) over the past 20 years to create new lighting. This investment has led to the successful development of technologies such as SunLike, which produces natural light that can alleviate the health effects of artificial indoor lighting, and No Wire Technology WICOP. With an overwhelming 18,000 patents in the LED industry, Seoul’s unique value in advanced technology has been recognized once again in this litigation.
Chung Hoon Lee, Seoul’s founder and CEO, said, “Immoral companies continue to sell infringing products by simply changing a product’s name even after patent infringement judgments, and some large corporations knowingly use infringing products to save a few cents. It drives young startup founders and innovative companies to despair.”
Mr. Lee was born as the son of a farmer and, by mortgaging his home, rented a corner of a commercial building and invested nearly $100 million annually in research and development. Through this effort, he built Seoul Semiconductor and Seoul Viosys into today’s global LED companies with an overwhelming 18,000 patents.
Seoul believes that while the fate given to us from birth cannot be controlled, opportunities in society should be fair so that young people and companies can achieve success.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 18,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies. Seoul Semiconductor also mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products like mobile phones, computer displays, and other applications, as well as the UV area. Seoul’s world first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en, YouTube, LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240925330051/en/
Contacts
Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom